Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Hilal Zivali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Pyrimidines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 49 Literaturangaben. Gefördert von: The authors received no specific funding for this study..
Abstract (Originalsprache)
Ovarian cancer remains one of the most lethal gynecological malignancies, underscoring the need for novel therapeutic strategies. In this study, a series of pyrimidine‐based nucleobase ( 7–14 ) and nucleoside ( 21–24 ) analogs were synthesized and evaluated for their potential anticancer activity through poly(ADP‐ribose) polymerase (PARP) inhibition. These compounds were tested for in vitro cytotoxicity on ovarian cancer cell lines OVCAR‐3 and KURAMOCHI. Among the synthesized derivatives—namely, 4‐(4‐substituted phenylamino)‐1‐cyclopentyl‐5‐( H /methyl)pyrimidine‐2(1 H )‐ones ( 7–14 ) and 4‐(4‐substituted phenylamino)‐1‐(β‐ d ‐ribofuranosyl)‐5‐methylpyrimidine‐2(1 H )‐ones ( 21–24 )—compound 8 exhibited the most potent cytotoxic activity. It significantly reduced cell viability in OVCAR‐3 (IC 50 = 27.1 ± 4.56 µM) and KURAMOCHI (IC 50 = 46.2 ± 4.87 µM) cells, outperforming the reference PARP inhibitor olaparib (IC 50 = 75.8 ± 6.1 µM for OVCAR‐3, IC 50 = 84.5 ± 11.4 µM for KURAMOCHI). These results suggest that compound 8 is a promising lead candidate for further development as an anticancer agent targeting PARP in ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
- Department of Pharmaceutical Chemistry, Institute of Health Sciences, Ankara University, Ankara, Turkey.
- Research, Center for Translational Medicine (KUTTAM), Koç University, İstanbul, Turkey.
- Koç University Graduate School of Health Sciences, Istanbul, Turkey.
- Department of Medical Biology, School of Medicine, Koç University, İstanbul, Turkey.
ORCID-Profile: Arya Akdağ, İrem Durmaz Şahin, Meral Tunçbilek
Förderung
- The authors received no specific funding for this study.
Zitieren
APA
Zivali, H., Akdağ, A., Demirkan, B., Durmaz Şahin, İ., & Tunçbilek, M. (2025). Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70117
Vancouver
Zivali H, Akdağ A, Demirkan B, Durmaz Şahin İ, Tunçbilek M. Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70117
BibTeX
@article{Zivali2025,
author = {Zivali, Hilal and Akdağ, Arya and Demirkan, Büşra and Durmaz Şahin, İrem and Tunçbilek, Meral},
title = {Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70117}
}
EUVIMED